Houston, TX., — Coya Therapeutics, Inc., (Coya), a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells (Tregs) and Treg-derived exosome therapeutics for neurodegenerative and autoimmune diseases, presented a corporate overview by Howard Berman, Ph.D., Chief Executive Officer of Coya Therapeutics, at the Oppenheimer Rare & Orphan Disease Summit held virtually on May 21, 2021.
Oppenheimer Rare & Orphan Disease Summit
Location:
